• Citer

European studies with adriamycin (NSC 123127) in lung cancer

par Rozencweig, Marcel ;Kenis, Yvon
Référence CANCER CHEMOTHER.REP., 6, 2, page (343-347)
Publication Publié, 1975

Article révisé par les pairs

• Détails
• Contenu

Résumé :

European clinical trials in lung cancer involving adriamycin used alone or in combination with other agents are briefly reviewed. Adriamycin has clearly shown a definite efficacy against bronchogenic carcinoma apparently without cell type specificity, yet the survival is not markedly increased. An intermittent high dose schedule is well tolerated; however, this schedule does not seem to reduce the dose related cardiac toxic effects. No conclusive data are available with regard to the value of adriamycin in combination with other chemotherapeutic agents and with other treatment modalities.